AstraZeneca (AZN) Tops Q3 EPS by 90c, Beats on Revenue

AstraZeneca (NASDAQ: AZN) reported Q3 EPS of $1.67, $0.90 better than the analyst estimate of $0.77. Revenue for the quarter came in at $10.98 billion versus the consensus estimate of $10.78 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings